The FDA approved a new generic version of the abortion pill mifepristone, prompting criticism from anti-abortion groups and Republican politicians, amid ongoing political and legal debates over abortion access in the U.S.
The FDA approved a generic version of the abortion pill mifepristone, sparking outrage among anti-abortion groups who oppose expanded access, despite extensive evidence supporting the drug's safety and efficacy. The approval is seen as a victory for evidence-based medicine by supporters, amid ongoing political and legal debates.
The FDA quietly approved a second generic version of the abortion pill mifepristone from Evita Solutions, just before a government shutdown, amid ongoing debates over its safety and access, with strong support from reproductive health advocates and opposition from anti-abortion groups.
Johnson & Johnson has reached an agreement with nonprofit Stop TB Partnership to allow the distribution of a generic version of its tuberculosis drug, bedaquiline, in low- and middle-income countries. This move will significantly expand access to the life-saving drug, which is currently priced out of reach for many communities. The agreement enables the nonprofit to sell generic versions of the drug in 44 countries where Johnson & Johnson's patents are still in effect. This will help lower the cost of the drug and make it more affordable for those in need.